Bleeding assessment
Welcome to our bleeding assessment
Finding out if you bleed too much isn't always easy. This test was developed to help you and your doctor find out if your bleeding is normal or not.
The questionnaire is adapted from a scientifically validated tool adapted by Professor Corrales and Professor Erik Berntorp1,2,3,4.
DISCLAIMER
PLEASE NOTE: This questionnaire is adapted from a scientifically validated tool adapted by Professor Corrales and Professor Erik Berntorp1,2,3,4 . It is intended for informational purposes only and to support a conversation with a qualified, licensed healthcare professional. It is in no way intended to be a substitute for professional medical advice and judgement. You should consult with your doctor or healthcare professional should you have questions or concerns concerning the results of this test.
PERSONAL DATA: Before taking this test, we wish to make you aware of the following information concerning your privacy:
- The answers that you provide in this test are used to create a risk score for von Willebrand disease (VWD)
- The data that you enter into this form will also be stored and used by Octapharma AG for statistical purposes only concerning VWD prevalence, and will only concern such data as is relevant and adequate for this purpose
- At no time will you be asked to provide any data that renders you personally identifiable
- The user ID that is entered by "returning visitors" only enables a second assessment taken to be directly linked to a first assessment previously taken. The form structure of the second assessment is identical to the first assessment. At no point will the user be personally identifiable
For more information please consult the data privacy statement.
1. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).
Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, et al. J Thromb Haemost. 2006; 4: 766-73.
2. A need to increase von Willebrand disease awareness: vwdtest.com/st - A global initiative to help address this gap. Corrales-Medina FF, Federici AB, Srivastava A, Dougall A, Millar CM, et al. Blood Rev. 2023; 58: 101018.
3. Rodeghiero F et al. J Thromb Haemost 2010;8: 2063-5
4.Deforest M et al. Haemophilia 2015 ;21 :e384-388
Have any members of your immediate family* been diagnosed with a bleeding disorder?
*Parents, siblings or children
Step {{questionIndex+1}}/{{questions.length}}
Your bleeding score is abnormal
This indicates that you may have a bleeding disorder.
Your Score
{{nbPointsAnswers}}
Normal range: 0-3
Thank you for taking the test. We recommend that you download the results letter and discuss the results with your doctor. There is a good chance that your bleeding is manageable, and your doctor will help find the right treatment for you.
Do you wonder if other family members also bleed too much? Please ask them to take the test
Your bleeding score is normal
If you bleed more in the future, please repeat the test. And if you are unsure about your bleeding, please consult a doctor.
Your Score
{{nbPointsAnswers}}
Normal range: 0-3
User ID: {{assessmentId}}
Your bleeding score indicates that you may have a bleeding disorder. However, this test is not a replacement for a complete assessment by a trained healthcare professional, and further information would be needed to make a proper diagnosis.
Please follow the steps below to ensure a full diagnosis.
Centers recommended for following up on the results with a von Willebrand specialist near your current location.
This letter is addressed to Health Care Professionals 999
Dear Colleagues,
My name is Erik Berntorp and I am a Professor in Haematology and Coagulation Disorders at Lund University in Sweden. As you may be aware, von Willebrand disease (VWD) is the most common bleeding disorder (affecting up to 1% of the world’s population) yet is still highly underdiagnosed. Together with other colleagues we have developed the VWDtest.com online platform, with the aim of improving the diagnosis of VWD. At the VWDtest.com website, users can complete a simple five-minute questionnaire to evaluate whether they may have a bleeding disorder or not.
In this case, the questionnaire has indicated that the user may have a bleeding disorder. We are here to help you identifying whether this person is affected by VWD. The support we provide includes advice on VWD diagnosis from world-leading experts as well as blood and plasma sample analysis in state of the art laboratories. These services are free of charge if the procedures below are strictly followed.
I hope you will benefit from the support of the VWDtest.com team and help us facilitating accurate VWD diagnosis.
How to proceed
- Following an abnormal bleeding test score, the individual has been asked to repeat the online bleeding questionnaire with their General Practitioner/Primary Care physician (GP/PCP). If this is you, please jump to the section “For GP/PCP” below.
- If the bleeding test results were similar when the test was repeated, the GP/PCP has been asked to refer the patient to a haematologist. If this is you, please jump to the section “For the haematologist” below.
For the GP/PCP
Please repeat the bleeding questionnaire together with your patient using the user ID (on the top right on the bleeding questionnaire results). Please don’t share more patient’s personal data than necessary for this purpose and please always adhere to the applicable data protection laws and regulations.
In case the bleeding score of your patient is 4 or above, please refer them to a haematologist. Please ensure that the haematologist is provided with the bleeding questionnaire results and informed about the purpose of this investigation.
In case the score is 3 or below, the patient does not need further investigation.
For the haematologist
Before contacting the VWD expert team, please execute the following blood tests:
- Complete blood count
- Activated partial thromboplastin time (APTT)
- Prothrombin time (PT)
- Fibrinogen
- Platelet function assay (PFA)
Abnormalities in the above mentioned laboratory tests, together with a clinical anamnestic patient data could give a sign for VWD. You have the possibility to contact and discuss your patient condition with our VWD expert team.
After having performed these blood tests, please contact the VWD expert team:
If you have any clinical questions about VWD, please send an email to Dr. Fernando Corrales (ffc5@med.miami.edu) if you are located in the continent of America and to Prof. Erik Berntorp (erik.berntorp@med.lu.se) if you are located anywhere else in the world stating your name, affiliation contact details and question(s). Please share the results from the bleeding questionnaire and blood tests.
Please don’t share more patient’s personal data than necessary for this purpose and please always adhere to the applicable data protection laws and regulations.
For a free sample analysis service (this service is not available in the United States) helping you to diagnose VWD, please send an email to Dr. Anna Pavlova (Anna.Pavlova@ukbonn.de) stating your name, affiliation contact details and question(s). Please share the results from the bleeding questionnaire and blood tests.
Again, please don’t share more patient’s personal data than necessary for this purpose and please always adhere to the applicable data protection laws and regulations.
Your email will be processed by the respective VWD expert, who will reply to you shortly. If you and the VWD expert team decide that further diagnostic tests are necessary, you may be asked to submit blood and plasma samples from your patient for analysis (detailed information on how to submit the samples will be provided to you). The submitted samples will undergo several tests, which may include: von Willebrand factor (VWF) antigen and activity levels, FVIII activity, VWF multimer analysis, and FVIII-binding assays. These tests will confirm or exclude whether the patient has VWD. In addition, if a VWD diagnosis is made, next-generation sequencing will be carried out to look for possible causative variations in the VWF gene.
This sample analysis service is free of charge, but only available upon explicit written request by a member of the VWD expert team. Any unsolicited sample submissions will be disregarded.
Support and advice on diagnosis and management options will continue to be available from the VWD expert team, free of charge, after the sample analysis results have been provided.
Yours sincerely,
Professor Erik Berntorp
This letter is addressed to Health Care Professionals
Dear Colleagues,
My name is Erik Berntorp and I am a Professor in Haematology and Coagulation Disorders at Lund University in Sweden. As you may be aware, von Willebrand disease (VWD) is the most common bleeding disorder (affecting up to 1% of the world’s population) yet is still highly underdiagnosed. Together with other colleagues we have developed the vwdtest.com/st online platform, with the aim of improving the diagnosis of VWD. At the vwdtest.com/st website, users can complete a simple five-minute questionnaire to evaluate whether they may have a bleeding disorder or not.
In this case, the questionnaire has indicated that the user may have VWD. We are here to help you identifying whether this person is affected by VWD. The support we provide includes advice on VWD diagnosis from world-leading experts as well as blood and sample analysis in state of the art laboratories in some countries. In these countries the services are offered free of charge if the procedures are strictly followed.
I hope you and your patients will benefit from the support of the vwdtest.com/st team and help us to facilitate accurate VWD diagnosis.
How to proceed
– Following an abnormal bleeding test score, the individual has been asked to repeat the online bleeding questionnaire with their General Practitioner/Primary Care physician (GP/PCP). If this is you, please jump to the section “For GP/PCP” below.
– If the bleeding test results were similar when the test was repeated, the GP/PCP has been asked to refer the patient to a haematologist. If this is you, please jump to the section “For the haematologist” below.
For the GP/PCP
Please repeat the bleeding questionnaire together with your patient using the user ID (on the top right on the bleeding questionnaire results). Please don’t share more patient’s personal data than necessary for this purpose and please always adhere to the applicable data protection laws and regulations.
In case the bleeding score of your patient is 4 or above, please refer them to a haematologist. Please ensure that the haematologist is provided with the bleeding questionnaire results and informed about the purpose of this investigation.
For the haematologist
Before contacting the VWD expert team, please execute the following blood tests:
- Complete blood count
- Activated partial thromboplastin time (APTT)
- Prothrombin time (PT)
- Fibrinogen
- Platelet function assay (PFA)
Abnormalities in the above mentioned laboratory tests, together with clinical anamnestic patient data could indicate VWD. You have the possibility to contact and discuss your patients condition with our VWD expert team.
After performing these blood tests and if you have any clinical questions about VWD, please send an email to Dr. Fernando Corrales (ffc5@med.miami.edu) if you are located in the continent of America and to Prof. Erik Berntorp (erik.berntorp@med.lu.se) if you are located anywhere else in the world stating your name, affiliation contact details and question(s). Please share the results from the bleeding questionnaire and blood tests.
Please don’t share more patient’s personal data than necessary for this purpose and please always adhere to the applicable data protection laws and regulations.
In some countries we offer a free sample analysis service helping you to diagnose VWD. If you would like to receive further information about this service and to enquire if it is available in your country please send an email to VWDtest_service@octapharma.com stating your name, affiliation contact details and question(s). Your email will be processed by a member of the vwdtest.com/st team, who will reply to you shortly.
If this service is available in your country then please share the results from the bleeding questionnaire and blood tests, again please don’t share more patient personal data than necessary for this purpose and please always adhere to the applicable data protection laws and regulations.
If you and the VWD expert team decide that further diagnostic tests are necessary, you may be asked to submit blood and plasma samples from your patient for analysis (detailed information on how to submit the samples will be provided to you). The submitted samples will undergo several tests, which may include: von Willebrand factor (VWF) antigen and activity levels, FVIII activity, VWF multimer analysis, and FVIII-binding assays. These tests will confirm or exclude whether the patient has VWD. In addition, if a VWD diagnosis is made, next-generation sequencing will be carried out to look for possible causative variations in the VWF gene.
If the service is available in your country it will be provided free of charge, but only upon confirmation by the vwdtest.com/st team and adherence to the processes in place. Any unsolicited sample submissions will be disregarded.
Support and advice on diagnosis and management options will continue to be available from the VWD expert team free of charge.
Yours sincerely,
Professor Erik Berntorp and
Fernando Corrales-Medina
{{assessmentId}}
{{userInformation.email}}
{{userInformation.sex}}
{{userInformation.age}}
{{userInformation.familyHistory}}
Country: {{userInformation.country}} - Region: {{userInformation.region}}
{{question.questionTitle}}
{{question.selectedAnswer.title}}
Processing of Personal Data by Octapharma AG
The following personal data will be provided to Octapharma AG for the purpose of the sample analysis service and therefore, solely for the coordination of the shipping of the samples: Name and affiliation and email address of the hematologist requesting the sample analysis service.
Only if needed by law/codex or necessary for the purpose of the relevant services, such information is shared with other legal entities within Octapharma.
The transfer to the group companies is based on the same legal ground as the processing as such. In order to ensure that the personal data is protected, Octapharma has entered into an Intercompany Data Transfer Agreement with its affiliated companies.
Moreover, Octapharma might engage service providers to process personal data on behalf of Octapharma. Such service providers may only process the personal data in accordance with Octapharma’s express instructions and may not use the data for their own purposes.
You have the right to request to be informed about the personal data which are processed/stored with Octapharma.
You have the right to request any corrections or modifications of personal data, which are incorrect.
For natural persons located in the EU/EEA/CH: Additionally, if a data subject has any issues with Octapharma’s processing of personal data, the data subject has the right to lodge a complaint with the competent data protection authority.
A data subject has, in addition to the rights outlined above, a right to object to certain processing of personal data, a right to request restriction of the processing of personal data, and a right to data portability. The right to data portability covers such personal data which Octapharma processes in electronic form.
Octapharma will store the information for such period as is necessary in order for Octapharma to satisfy legal or other obligations, or in order for Octapharma to establish, defend or exercise legal claims. When the personal data is no longer necessary for these purposes, the personal data will be securely deleted, taking into account retention times subject to local laws. For questions or requests concerning your personal data, please send an e-mail to: dataprivacy@octapharma.com.
This letter is addressed to Health Care Professionals
Dear Colleagues,
My name is Erik Berntorp and I am a Professor in Haematology and Coagulation Disorders at Lund University in Sweden. As you may be aware, von Willebrand disease (VWD) is the most common bleeding disorder (affecting up to 1% of the world’s population) yet is still highly underdiagnosed. Together with other colleagues we have developed the vwdtest.com/st online platform, with the aim of improving the diagnosis of VWD. At the vwdtest.com/st website, users can complete a simple five-minute questionnaire to evaluate whether they may have a bleeding disorder or not.
In this case, the questionnaire has indicated that the user may have VWD. We are here to help you identifying whether this person is affected by VWD. The support we provide includes advice on VWD diagnosis from world-leading experts as well as blood and sample analysis in state of the art laboratories in some countries. In these countries the services are offered free of charge if the procedures are strictly followed.
I hope you and your patients will benefit from the support of the vwdtest.com/st team and help us to facilitate accurate VWD diagnosis.
How to proceed
– Following an abnormal bleeding test score, the individual has been asked to repeat the online bleeding questionnaire with their General Practitioner/Primary Care physician (GP/PCP). If this is you, please jump to the section “For GP/PCP” below.
– If the bleeding test results were similar when the test was repeated, the GP/PCP has been asked to refer the patient to a haematologist. If this is you, please jump to the section “For the haematologist” below.
For the GP/PCP
Please repeat the bleeding questionnaire together with your patient using the user ID (on the top right on the bleeding questionnaire results). Please don’t share more patient’s personal data than necessary for this purpose and please always adhere to the applicable data protection laws and regulations.
In case the bleeding score of your patient is 4 or above, please refer them to a haematologist. Please ensure that the haematologist is provided with the bleeding questionnaire results and informed about the purpose of this investigation.
For the haematologist
Before contacting the VWD expert team, please execute the following blood tests:
- Complete blood count
- Activated partial thromboplastin time (APTT)
- Prothrombin time (PT)
- Fibrinogen
- Platelet function assay (PFA)
Abnormalities in the above mentioned laboratory tests, together with clinical anamnestic patient data could indicate VWD. You have the possibility to contact and discuss your patients condition with our VWD expert team.
After performing these blood tests and if you have any clinical questions about VWD, please send an email to Dr. Fernando Corrales (ffc5@med.miami.edu) if you are located in the continent of America and to Prof. Erik Berntorp (erik.berntorp@med.lu.se) if you are located anywhere else in the world stating your name, affiliation contact details and question(s). Please share the results from the bleeding questionnaire and blood tests.
Please don’t share more patient’s personal data than necessary for this purpose and please always adhere to the applicable data protection laws and regulations.
In some countries we offer a free sample analysis service helping you to diagnose VWD. If you would like to receive further information about this service and to enquire if it is available in your country please send an email to VWDtest_service@octapharma.com stating your name, affiliation contact details and question(s). Your email will be processed by a member of the vwdtest.com/st team, who will reply to you shortly.
If this service is available in your country then please share the results from the bleeding questionnaire and blood tests, again please don’t share more patient personal data than necessary for this purpose and please always adhere to the applicable data protection laws and regulations.
If you and the VWD expert team decide that further diagnostic tests are necessary, you may be asked to submit blood and plasma samples from your patient for analysis (detailed information on how to submit the samples will be provided to you). The submitted samples will undergo several tests, which may include: von Willebrand factor (VWF) antigen and activity levels, FVIII activity, VWF multimer analysis, and FVIII-binding assays. These tests will confirm or exclude whether the patient has VWD. In addition, if a VWD diagnosis is made, next-generation sequencing will be carried out to look for possible causative variations in the VWF gene.
If the service is available in your country it will be provided free of charge, but only upon confirmation by the vwdtest.com/st team and adherence to the processes in place. Any unsolicited sample submissions will be disregarded.
Support and advice on diagnosis and management options will continue to be available from the VWD expert team free of charge.
Yours sincerely,
Professor Erik Berntorp
Your bleeding score: {{nbPointsAnswers}}
Your bleeding score is abnormal
Your bleeding score is normal
{{testDate}}
{{assessmentId}}
{{userInformation.sex}}
{{userInformation.age}}
{{userInformation.familyHistory}}
Country: {{userInformation.country}} - Region: {{userInformation.region}}
{{question.questionTitle}}
{{question.selectedAnswer.title}}
Your bleeding score:Your bleeding score: {{previousAssessmentData.score}}
Your bleeding score is abnormal
Your bleeding score is normal
{{previousAssessmentDate}}
{{previousAssessmentId}}
{{previousAssessmentData.sex}}
{{previousAssessmentData.age}}
{{previousAssessmentData.family_history}}
Country: {{previousAssessmentData.country}} - Region: {{previousAssessmentData.region}}
{{answer.question_title}}
{{answer.answer_title}}
Processing of Personal Data by Octapharma AG
The following personal data will be provided to Octapharma AG for the purpose of the sample analysis service and therefore, solely for the coordination of the shipping of the samples: Name and affiliation and email address of the hematologist requesting the sample analysis service.
Only if needed by law/codex or necessary for the purpose of the relevant services, such information is shared with other legal entities within Octapharma.
The transfer to the group companies is based on the same legal ground as the processing as such. In order to ensure that the personal data is protected, Octapharma has entered into an Intercompany Data Transfer Agreement with its affiliated companies.
Moreover, Octapharma might engage service providers to process personal data on behalf of Octapharma. Such service providers may only process the personal data in accordance with Octapharma’s express instructions and may not use the data for their own purposes.
You have the right to request to be informed about the personal data which are processed/stored with Octapharma.
You have the right to request any corrections or modifications of personal data, which are incorrect.
For natural persons located in the EU/EEA/CH: Additionally, if a data subject has any issues with Octapharma’s processing of personal data, the data subject has the right to lodge a complaint with the competent data protection authority.
A data subject has, in addition to the rights outlined above, a right to object to certain processing of personal data, a right to request restriction of the processing of personal data, and a right to data portability. The right to data portability covers such personal data which Octapharma processes in electronic form.
Octapharma will store the information for such period as is necessary in order for Octapharma to satisfy legal or other obligations, or in order for Octapharma to establish, defend or exercise legal claims. When the personal data is no longer necessary for these purposes, the personal data will be securely deleted, taking into account retention times subject to local laws. For questions or requests concerning your personal data, please send an e-mail to: dataprivacy@octapharma.com.